ROCHE’S CORONA DRUG FAILS COVID-19 TESTING
While the efforts for vaccination and medicine continue in many parts of the world within the scope of combating the Corona virus epidemic, the Swiss-based pharmaceutical company Roche announced that the hopes have fallen in the final stage of the developed drug test.
He explained that Roche’s ongoing studies on severe Covid-19 patients did not yield positive results. In the statement made by Roche, which explains that the studies started on March in 330 patients, the expression “Roche’s Actemra / RoActemra drug was not effective in the last clinical studies conducted in patients diagnosed with pneumonia” was used.
In the statement, “The expected clinical result in COVACTA trials could not be achieved. At the beginning of the trials, it was aimed to reduce the pneumonia associated with Covid-19 and to decrease the mortality rate due to the corona virus. ”
Roche predicted that the drug would achieve positive results, increasing the amount of drugs produced to 1 million instead of the few hundred thousand drugs previously described. While Roche explained that the drug heals patients faster, it was stated that this is not the primary purpose of the drug. According to official data, the drug developed by Roche can heal patients on average in 8 days.